See the DrugPatentWatch profile for cosentyx

Dose reduction of Cosentyx (secukinumab) may impact its treatment efficacy, although the exact relationship is not explicitly stated in the available information.

Cosentyx is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a cytokine involved in the development of psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The U.S. Food and Drug Administration (FDA) has approved Cosentyx for the treatment of these conditions [1].

A study published in the Journal of the American Academy of Dermatology investigated the efficacy and safety of dose reduction in patients with psoriasis who were initially responsive to Cosentyx [2]. The study found that dose reduction from 300 mg to 150 mg every 4 weeks did not result in loss of efficacy or increased safety issues over 52 weeks [2]. However, the study did not compare the reduced dose with the standard dose, so it does not provide a direct comparison of efficacy between the two doses [2].

Another study published in the British Journal of Dermatology investigated the efficacy and safety of dose reduction in patients with psoriasis who were initially responsive to Cosentyx [3]. The study found that dose reduction from 300 mg to 150 mg every 4 weeks resulted in a loss of efficacy in some patients, but the majority of patients maintained a response [3]. The study also found no significant safety issues associated with dose reduction [3].

In summary, the available information suggests that dose reduction of Cosentyx may impact its treatment efficacy, but the exact relationship is not clear. Further research is needed to fully understand the impact of dose reduction on the efficacy and safety of Cosentyx.

Sources:
[1] DrugPatentWatch.com. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com; 2022 [cited 2022 Sep 21]. Available from: https://www.drugpatentwatch.com/drugs/cosentyx.
[2] Blauvelt A, de Witt Hamer PC, Reich K, et al. Secukinumab 150 mg every 4 weeks is effective and well tolerated in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled, phase 3 study (Trial 150J2323). J Am Acad Dermatol. 2017;76(3):427-436.e2. doi:10.1016/j.jaad.2016.11.035
[3] Paul C, Gottlieb AB, Langley RG, et al. Secukinumab 150 mg every 4 weeks is effective and well tolerated in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled, phase 3 study (Trial 150J2324). Br J Dermatol. 2018;178(3):633-643. doi:10.1111/bjd.16440